Currentblue cross blue shield - tennesseePolicy N/A

Intracellular Micronutrient Analysis

This policy governs coverage and limitations for intracellular micronutrient testing (including proprietary panels such as SpectraCell, ExaTest, and Cell Science Systems CMA) for Blue Cross Blue Shield - Tennessee members. It applies to requests for these laboratory tests and their use in diagnosis or management.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyIntracellular Micronutrient Analysis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionExpect prior authorization to be denied for intracellular micronutrient panel testing unless a superseding government policy applies.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

No FDA clearanceFDA status

CLIALab accreditation

31SpectraCell nutrients

MultipleVendors

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

Not Medically Necessary / Not Covered

Not covered due to insufficient evidence

Main coverage stance: Intracellular micronutrient panel testing, including but not limited to SpectraCell, Cell Science Systems Cellular Micronutrient Assay (CMA), and ExaTest, does not meet coverage criteria due to lack of published scientific literature demonstrating that these tests are required and beneficial for diagnosis or treatment.

No controlled studies showing clinical utility or impact on management; no practice guidelines recommend testing.

This policy addresses intracellular micronutrient panel testing — proprietary or laboratory-developed assays that aim to assess intracellular stores of vitamins, minerals, amino acids, or antioxidants. Examples include the SpectraCell micronutrient panel, IntraCellular Diagnostics ExaTest, and Cell Science Systems Cellular Micronutrient Assay (CMA), among other vendor panels and LDTs offered by commercial laboratories. The policy applies to requests for these tests for Blue Cross Blue Shield - Tennessee members and governs coverage and limitations for their use in diagnosis or clinical management.

Intracellular micronutrient tests described in this policy are offered by commercial laboratories and include methods such as lymphocyte-based assays (SpectraCell, CMA) and buccal‑cell elemental analysis (ExaTest). These tests are performed in CLIA‑accredited laboratories but have not been cleared or approved by the FDA. Evidence supporting their clinical validity and utility is limited: no controlled studies demonstrate improved diagnostic accuracy or impact on patient management, and no professional practice guidelines recommend routine use of intracellular testing over standard serum nutrient measurements.

Use of intracellular micronutrient panel testing for screening in asymptomatic individuals, for personalizing dietary supplements or supplement regimens, or for routine periodic assessment of micronutrient status in the general population is considered not medically necessary. The literature search identified no recommendations or evidence that such testing changes management or improves health outcomes compared with standard approaches.

Covered Indications

No covered clinical indications are specified.

Covered indications: No clinical indications for intracellular micronutrient panel testing are identified as covered in this policy.

The document does not specify any covered indications; tests are offered as laboratory-developed tests and have not been FDA cleared or approved.

Provider Responsibilities & Authorization

Prior Authorization

Prior authorization expectation

Providers should expect prior authorization or denial risk for intracellular micronutrient panel testing. Intracellular micronutrient panel testing (e.g., SpectraCell, Cell Science Systems cell micronutrient assay, ExaTest) does not meet coverage criteria due to insufficient published evidence of clinical utility and therefore may be denied.

Examples: SpectraCell, IntraCellular Diagnostics ExaTest, Cell Science Systems CMA
Denial risk when submitted without documentation meeting an applicable government policy or demonstrating medical necessity

Note

Prior authorization — payer policy

This policy does not specify an internal prior authorization requirement; however, coverage determinations will follow the policy criteria and payer-specific administrative requirements.

Note

Preferred testing approach

Standard serum nutrient testing is the established approach; no clinical guidelines support intracellular testing and no studies demonstrate its clinical utility compared to standard testing.

Preferred approach: standard serum nutrient testing per usual clinical guidelines

Documentation Required

Government policy precedence

If there is a conflict between this policy and any applicable government policy (e.g., Medicare LCD/NCD or state Medicaid), the government policy supersedes and will be used for coverage determinations.

Follow applicable LCDs, NCDs, or state Medicaid rules when they differ from this policy

Documentation Required

Laboratory accreditation documentation

Laboratory-developed intracellular micronutrient tests are performed in CLIA-accredited high-complexity laboratories and have not undergone FDA clearance or approval; documentation submitted for coverage review should include CLIA accreditation and any laboratory validation information if available.

Document CLIA accreditation status for the performing laboratory
If available, include lab validation/verification data for the specific LDT

Denial Risk

Coverage denial trigger

Examples of intracellular micronutrient panel testing are considered noncovered under this policy and may trigger coverage denial unless an applicable government policy or specific documented medical necessity justifies coverage.

Noncovered examples: SpectraCell, IntraCellular Diagnostics ExaTest, Cell Science Systems CMA

Clinical Background

Micronutrients — vitamins and trace elements — are essential dietary components required in small amounts for metabolic and enzymatic functions. Deficiencies can impair physiologic processes and lead to clinical symptoms. Standard serum measurements are widely available but may be influenced by recent intake, inflammation, or physiologic stress and do not always reflect tissue stores. Intracellular methods have been proposed to better reflect longer‑term or tissue‑specific status; however, available data are limited and do not establish clinical utility for routine use.

Definitions and Terminology

CLIA definition — Clinical Laboratory Improvement Amendments

DefinitionCLIA = Clinical laboratories improvement amendments

Regulatory scopeCLIA (and CLIA '88) governs laboratory certification and standards for clinical testing

Acronym expansionCLIA '88 = Clinical laboratory improvement amendments of 1988

Intracellular micronutrient tests — examples of proprietary assays (SpectraCell, ExaTest, CMA)

SpectraCell micronutrient panelLymphocyte-based assay measuring growth with/without specific nutrients across ~31 micronutrients (vitamins, minerals, antioxidants)

ExaTest (IntraCellular Diagnostics)ASEM/Energy Dispersive X-Ray analysis of buccal epithelial cells to report intracellular electrolytes (e.g., Mg, Na, Ca, P, K, Cl)

Cell Science Systems CMACellular Micronutrient Assay measures mitogen-stimulated lymphocyte proliferation before and after nutrient addition to infer insufficiency

Laboratory-developed test (LDT) — definition and regulatory note (CLIA, not FDA-cleared)

DefinitionLaboratory-developed test (LDT) = a test developed and validated by a laboratory for in-house use

Regulatory noteLDTs are regulated by CMS as high-complexity tests under CLIA '88; they have not undergone FDA approval or clearance

Clinical implicationBeing an LDT means FDA approval/clearance is not required for clinical use, but tests must be validated by the performing laboratory

Ordering and Documentation

Billing Rule

Follow applicable government (LCD/NCD/state Medicaid) policies before ordering

Follow applicable government policies (LCD/NCD or state Medicaid) where they supersede this policy; consult the CMS Medicare Coverage Database or the applicable state Medicaid website for the most up-to-date guidance before ordering.

Visit CMS Medicare Coverage Database: http://www.cms.gov/medicare-coveragedatabase/overview-and-quick-search.aspx
Check the applicable state Medicaid website for current rules

Documentation Required

Ordering authority not specified — verify local rules

The document does not specify which clinicians or practitioners are authorized to order intracellular micronutrient tests; providers should use their usual ordering authority and verify any government or plan-specific ordering restrictions.

Not Covered Services

Intracellular micronutrient panel testing, including but not limited to SpectraCell, Cell Science Systems Cellular Micronutrient Assay (CMA), and IntraCellular Diagnostics ExaTest, does not meet coverage criteria under this policy due to insufficient published evidence demonstrating necessary benefit for diagnosis or treatment. Requests for these tests are subject to denial consistent with this coverage stance.

The tests referenced in this policy are performed in CLIA‑accredited laboratories but have not undergone FDA approval or clearance. Many are offered as laboratory‑developed tests (LDTs) that are validated and performed in‑house and regulated under CLIA as high‑complexity tests; the FDA has not approved or cleared these LDTs for clinical use.

OpenPayer

Intracellular Micronutrient Analysis

Coverage Determinations

Coding and Billing

Provider Responsibilities & Authorization

Clinical Background

Definitions and Terminology

Frequency and Retesting

Ordering and Documentation

Not Covered Services